Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplantation, Liver Clear all
Terminated Phase 2 Interventional Results available

Pentoxifylline Therapy in Biliary Atresia

NCT01774487
View directory record Official record
Conditions
Biliary Atresia
Interventions
Pentoxifylline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 180 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

NCT01624285
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
sorafenib tosylate, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Completed No phase listed Observational

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

NCT02182986
View directory record Official record
Conditions
Heart Transplant, Small Intestine Transplant, Kidney Transplant, Liver Transplant, EBV-Related PTLD, PTLDs
Interventions
transplant, Immunosuppressive Drugs
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782
View directory record Official record
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
Interventions
ECUR-506
Genetic
Lead sponsor
iECURE, Inc.
Industry
Eligibility
24 Hours to 7 Months · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

NCT00644761
View directory record Official record
Conditions
Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Study to Evaluate Performance of the Organ Recovery Systems LifePort® Liver Transporter System, a Machine Perfusion System, for Liver Transplant

NCT03484455
View directory record Official record
Conditions
Liver Transplantation
Interventions
Hypothermic machine perfusion, Static cold storage
Device
Lead sponsor
Organ Recovery Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Chicago, Illinois • Newark, New Jersey • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant

NCT00063648
View directory record Official record
Conditions
Liver Disease, Lymphoproliferative Disorders
Interventions
EBV-specific autologous CTL
Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Month to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
Biological · Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant

NCT00585858
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated No phase listed Observational

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

NCT02037373
View directory record Official record
Conditions
Coagulopathy, Endstage Liver Disease
Interventions
Octaplas™, Plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Loma Linda, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Examining the Use of a Novel Immersive Motion Tracking Upper Extremity Exercise Program for Acute Hospitalized Patients

NCT06222554
View directory record Official record
Conditions
Kidney Transplant, Liver Transplant
Interventions
MoveMend Health
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Liver Live Donor Champion Program

NCT03580629
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Liver Live Donor Champion Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting No phase listed Observational

Disparities Among Liver Transplant Patients

NCT05981196
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 4 Interventional Results available

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

NCT03625687
View directory record Official record
Conditions
Respiratory Failure, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 2 Interventional

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

NCT05103904
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Lenvatinib
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT03812289
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Starzl Network Patient Reported Outcomes

NCT05241847
View directory record Official record
Conditions
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions
PeLTQL delivery via electronic means
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Optimizing Kidney Transplant Informed Consent

NCT01859884
View directory record Official record
Conditions
End-stage Kidney Disease
Interventions
Inform Me: web-based education tool
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076
View directory record Official record
Conditions
Liver Disease
Interventions
mycophenolate mofetil
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 22, 2026, 8:17 PM EDT
Completed No phase listed Observational

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

NCT01300390
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 2 Interventional

Defibrotide Dose-escalation for SOS Post-HSCT

NCT05987124
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 8:17 PM EDT